TP53 and lung carcinoma: Of note, our data indicated that uL3 status is associated to chemoresistance since the loss of uL3 makes chemotherapeutic drugs, such as 5-FU, oxaliplatin (L-OHP), Actinomycin D, and Cisplatin ineffective in colon and lung cancer cells lacking active p53 [21,22,23,24].